ARS Pharmaceuticals, Inc. SPRY EBIT

EBIT at other companies

Aquestive Therapeutics, Inc.AQST

-$8.22M+27.7%

Amneal Pharmaceuticals, Inc.AMRX

$129.77M+16.5%

ViatrisVTRS

$6.3M-97.3%

AMP

Amphastar PharmaceuticalsAMPH

$39.73M-5.8%

Neuropace, Inc.NPCE

-$5.14M+37.2%

Eton Pharmaceuticals, Inc.ETON

$2.41M+614%

FAQ

What is ARS Pharmaceuticals, Inc.'s EBIT?

ARS Pharmaceuticals, Inc. (SPRY) reported EBIT of -$60.15M in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s EBIT changed year-over-year?

ARS Pharmaceuticals, Inc.'s EBIT decreased by 61.8% year-over-year, from -$37.18M to -$60.15M.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s EBIT?

Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s EBIT has grown at a 71.6% compound annual growth rate (CAGR), from -$35.52M to -$179.45M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.